Literature DB >> 15572155

Adaptive inhibitors of the HIV-1 protease.

Hiroyasu Ohtaka1, Ernesto Freire.   

Abstract

A significant obstacle to the efficacy of drugs directed against viral targets is the presence of amino acid polymorphisms in the targeted molecules. Amino acid polymorphisms may occur naturally due to the existence of variations within and between viral strains or as the result of mutations associated with drug resistance. An ideal drug will be one that is extremely effective against a primary target and maintains its effectiveness against the most important variations of the target molecule. A drug that simultaneously inhibits different variants of the target will lead to a faster suppression of the virus, retard the appearance of drug-resistant mutants and provide more efficacious and, in the long range, more affordable therapies. Drug molecules with the ability to inhibit several variants of a target with high affinity have been termed adaptive drugs (Nat. Biotechnol. 20 (2002) 15; Biochemistry 42 (2003) 8459; J. Cell. Biochem. S37 (2001) 82). Current drug design paradigms are predicated upon the lock-and-key hypothesis, which emphasizes shape complementarity as a way to attain specificity and improved binding affinity. Shape complementarity is accomplished by the introduction of conformational constraints in the drug molecule. While highly constrained molecules do well against a unique target, they lack the ability to adapt to target variations like those originating from naturally occurring polymorphisms or drug-resistant mutations. Targeting an array of closely related targets rather than a single one while still maintaining selectivity, requires a different approach. A plausible strategy for designing high affinity adaptive inhibitors is to engineer their most critical interactions (for affinity and specificity) with conserved regions of the target while allowing for adaptability through the introduction of flexible asymmetric functionalities in places facing variable regions of the target. The fundamental thermodynamics and structural principles associated with this approach are discussed in this chapter.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15572155     DOI: 10.1016/j.pbiomolbio.2004.07.005

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  39 in total

Review 1.  Finding a better path to drug selectivity.

Authors:  Yuko Kawasaki; Ernesto Freire
Journal:  Drug Discov Today       Date:  2011-08-02       Impact factor: 7.851

2.  Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid.

Authors:  Sandhya Kortagere; Navid Madani; Marie K Mankowski; Arne Schön; Isaac Zentner; Gokul Swaminathan; Amy Princiotto; Kevin Anthony; Apara Oza; Luz-Jeannette Sierra; Shendra R Passic; Xiaozhao Wang; David M Jones; Eric Stavale; Fred C Krebs; Julio Martín-García; Ernesto Freire; Roger G Ptak; Joseph Sodroski; Simon Cocklin; Amos B Smith
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

3.  Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

Authors:  José C Clemente; Roxana M Coman; Michele M Thiaville; Linda K Janka; Jennifer A Jeung; Sarawut Nukoolkarn; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Robert McKenna; Wichet Leelamanit; Maureen M Goodenow; Ben M Dunn
Journal:  Biochemistry       Date:  2006-05-02       Impact factor: 3.162

4.  Some binding-related drug properties are dependent on thermodynamic signature.

Authors:  Arne Schön; Navid Madani; Amos B Smith; Judith M Lalonde; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2011-02-02       Impact factor: 2.817

Review 5.  Adding calorimetric data to decision making in lead discovery: a hot tip.

Authors:  John E Ladbury; Gerhard Klebe; Ernesto Freire
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

Review 6.  Applying thermodynamic profiling in lead finding and optimization.

Authors:  Gerhard Klebe
Journal:  Nat Rev Drug Discov       Date:  2015-01-23       Impact factor: 84.694

7.  Enthalpy screen of drug candidates.

Authors:  Arne Schön; Ernesto Freire
Journal:  Anal Biochem       Date:  2016-08-25       Impact factor: 3.365

Review 8.  Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Authors:  Eric Lefebvre; Celia A Schiffer
Journal:  AIDS Rev       Date:  2008 Jul-Sep       Impact factor: 2.500

9.  Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.

Authors:  Xiaoqing Liu; Zhilong Xiu; Ce Hao
Journal:  J Comput Aided Mol Des       Date:  2009-02-15       Impact factor: 3.686

10.  Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: free energy calculation and molecular dynamic simulation.

Authors:  Jianzhong Chen; Shaolong Zhang; Xinguo Liu; Qinggang Zhang
Journal:  J Mol Model       Date:  2009-07-24       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.